Stockscreener 앱 받기
3.485
1.83%
-0.065
시간 외 거래:
3.49
0.005
+0.14%
전일 마감가:
$3.55
열려 있는:
$3.58
하루 거래량:
6,475
Relative Volume:
0.21
시가총액:
$165.21M
수익:
$27,600
순이익/손실:
$-36.04M
주가수익비율:
-4.3737
EPS:
-0.7968
순현금흐름:
$-1.66M
1주 성능:
+1.01%
1개월 성능:
+21.43%
6개월 성능:
-35.70%
1년 성능:
-54.14%
1일 변동 폭
$3.485
$3.64
1주일 범위
$3.34
$3.64
52주 변동 폭
$2.76
$7.97
나노바이오틱스 Stock (NBTX) Company Profile
NBTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
3.485 | 165.21M | 27,600 | -36.04M | -1.66M | -0.7968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
나노바이오틱스 Stock (NBTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-28 | 개시 | Guggenheim | Buy |
| 2023-12-08 | 개시 | Leerink Partners | Outperform |
| 2021-01-06 | 개시 | Evercore ISI | Outperform |
나노바이오틱스 주식(NBTX)의 최신 뉴스
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study - Yahoo Finance
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN International
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
나노바이오틱스 (NBTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):